A 24 week Randomized Double-Blind, Placebo-Controlled Study followed by 72 week open-label extension to assess the efficacy, safety and tolerability of drisapersen sodium in subjects with Duchenne Muscular Dystrophy
Latest Information Update: 21 Jul 2016
At a glance
- Drugs Drisapersen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 21 Jul 2016 Status changed from recruiting to completed.
- 14 Jul 2016 New trial record